Related Experiment Video
Updated: May 26, 2026
09:06
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
H3K27M-driven hypertranscription leads to a new targetable dependency in diffuse midline gliomas
Biorxiv : the Preprint Server for Biology
|May 25, 2026
Summary
Diffuse midline gliomas (DMGs) exhibit H3K27M-induced hypertranscription, a vulnerability exploitable by ATR inhibitors. This study supports clinical trials of ATR inhibition for aggressive pediatric brain tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse midline gliomas (DMGs) are aggressive pediatric brain tumors driven by the H3K27M oncohistone.
- Current treatments for DMGs lack curative potential, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify H3K27M-induced oncogenic vulnerabilities in DMGs.
- To investigate the therapeutic potential of targeting H3K27M-driven hypertranscription.
Main Methods:
- Utilized genetic mouse models, human DMG cell lines, and primary tumor specimens.
- Assessed the effects of H3K27M on transcription and replication stress.
- Evaluated the efficacy of the ATR inhibitor alnodesertib in vitro and in vivo.
Main Results:
- H3K27M drives hypertranscription in DMGs, leading to replication stress.
- ATR inhibition, specifically with alnodesertib, demonstrated therapeutic efficacy.
- Alnodesertib showed synergistic activity with radiotherapy in preclinical models.
Conclusions:
- Hypertranscription is a key molecular feature and therapeutic vulnerability in H3K27M-driven DMGs.
- ATR inhibition represents a promising therapeutic strategy for DMGs, warranting clinical trials.
- ATR inhibition may benefit other aggressive cancers characterized by hypertranscription.
